Pfizer Q3 2024 Adj. EPS $1.06 Beats $0.62 Estimate, Sales $17.702B Beat $14.954B Estimate
Portfolio Pulse from Benzinga Newsdesk
Pfizer reported its Q3 2024 financial results, with adjusted EPS of $1.06, surpassing the estimated $0.62. The company's sales reached $17.702 billion, exceeding the expected $14.954 billion.
October 29, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's Q3 2024 earnings report shows strong performance, with EPS and sales both exceeding analyst expectations.
Pfizer's better-than-expected EPS and sales figures suggest strong operational performance, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100